CME REVIEW ARTICLE
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature

https://doi.org/10.1016/S1081-1206(10)61112-XGet rights and content

Objective

To perform a comprehensive review of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Data Sources

A MEDLINE search was performed for the years 1975 to 2003 using the keywords Stevens-Johnson syndrome and toxic epidermal necrolysis to identify relevant articles published in English in peer-reviewed journals.

Study Selection

All clinical studies that reported on 4 or more patients, review articles, and experimental studies that concerned disease mechanisms were selected and further analyzed. Clinical reports that included fewer than 4 patients were selected only if they were believed to carry a significant message about disease mechanism or therapy.

Results

Stevens-Johnson syndrome and toxic epidermal necrolysis seem to be variants of the same disease with differing severities. A widely accepted consensus regarding diagnostic criteria and therapy does not exist at present. Despite the recent experimental studies, the pathogenic mechanisms of these diseases remain unknown. Although progress in survival through early hospitalization in specialized burn units has been made, the prevalence of life-long disability from the ocular morbidity of Stevens-Johnson syndrome and toxic epidermal necrolysis has remained unchanged for the past 35 years. Further progress depends on modification of the acute phase of the disease rather than continuation of supportive care. The available published evidence indicates that a principal problem in the pathogenesis is immunologic and that immunomodulatory intervention with short-term, high-dose intravenous steroids or intravenous immunoglobulin holds the most promise for effective change in survival and long-term morbidity.

Conclusions

The results of this review call for a widely accepted consensus on diagnostic criteria for Stevens-Johnson and toxic epidermal necrolysis and multicenter collaboration in experimental studies and clinical trials that investigate disease mechanisms and novel therapeutic interventions, respectively.

REFERENCES (180)

  • M Heng et al.

    Efficacy of cyclophosphamide in toxic epidermal necrolysis

    J Am Acad Dermatol

    (1991)
  • N Birchall et al.

    Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin

    J Am Acad Dermatol

    (1987)
  • WW Howland et al.

    Erythema multiforme: clinical, histopathologic, and immunologic study

    J Am Acad Dermatol

    (1984)
  • K Nishida et al.

    Epithelial hyperproliferation and transglutaminase 1 gene expression in Stevens-Johnson syndrome conjunctiva

    Am J Pathol

    (1999)
  • P Wolkenstein et al.

    Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis

    Lancet

    (1998)
  • FA Krumlovsky et al.

    Renal disease associated with toxic epidermal necrolysis (Lyell's disease) (Lyell's disease)

    Am J Med

    (1974)
  • JC Roujeau et al.

    Toxic epidermal necrolysis (Lyell syndrome)

    Am J Acad Dermatol

    (1990)
  • JE Rasmussen

    Toxic epidermal necrolysis

    Med Clin North Am

    (1980)
  • JA Thompson et al.

    A case of contact dermatitis, erythema multiforme, and toxic epidermal necrolysis

    J Am Acad Dermatol

    (1981)
  • AM Stevens et al.

    A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children

    Am J Dis Child

    (1922)
  • BA Thomas

    The so-called Stevens-Johnson syndrome

    BMJ

    (1950)
  • S Bastuji-Garin et al.

    Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme

    Arch Dermatol

    (1993)
  • JC Roujeau

    The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification

    J Invest Dermatol

    (1994)
  • H Assier et al.

    Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes

    Arch Dermatol

    (1995)
  • A Lyell

    Requiem for toxic epidermal necrolysis

    Br J Dermatol

    (1990)
  • JC Roujeau

    Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme

    J Dermatol

    (1997)
  • JC Huff et al.

    Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes

    J Am Acad Dermatol

    (1983)
  • S Inachi et al.

    Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome: contribution of perforin-positive cell infiltration

    Arch Dermatol

    (1997)
  • HC Ting et al.

    Erythema multiforme: response to corticosteroid

    Dermatologica

    (1984)
  • B Rzany et al.

    Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis

    Br J Dermatol

    (1996)
  • DM Porteous et al.

    Severe cutaneous reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection

    Arch Dermatol

    (1991)
  • HL Chan et al.

    The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients

    Arch Dermatol

    (1990)
  • E Schopf et al.

    Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany

    Arch Dermatol

    (1991)
  • BL Strom et al.

    A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposure

    Arch Dermatol

    (1991)
  • D Capella et al.

    European network for the case-population surveillance of rare diseases (Euronet): a prospective feasibility study

    Eur J Clin Pharmacol

    (1998)
  • DW Kaufman

    Epidemiologic approaches to the study of toxic epidermal necrolysis

    J Invest Dermatol

    (1994)
  • JC Roujeau et al.

    Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

    N Engl J Med

    (1995)
  • P Wolkenstein et al.

    Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants

    Arch Dermatol

    (1995)
  • R Patterson et al.

    Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding patho-genesis

    Ann Allergy

    (1994)
  • R Patterson et al.

    StevensJohnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS

    Allergy Proc

    (1992)
  • BJ Mondino et al.

    HLA antigens in Stevens-Johnson syndrome with ocular involvement

    Arch Ophthalmol

    (1982)
  • N Tsuroda et al.

    Rapidly progressive bronchiolitis obliterans associated with Stevens-Johnson syndrome

    Chest

    (1990)
  • L Naldi et al.

    Incidence of toxic epidermal necrolysis in Italy

    Arch Dermatol

    (1990)
  • LE Bottiger et al.

    Drug induced febrile mucocutaneous syndrome

    Acta Med Scand

    (1975)
  • JA Marvin et al.

    Improved treatment of the Stevens-Johnson syndrome

    Arch Surg

    (1984)
  • T McGee et al.

    Toxic epidermal necrolysis syndrome: mortality reduced with early referral to regional burn center

    Plast Reconstr Surg

    (1998)
  • L Singer et al.

    Vitamin A in Stevens-Johnson syndrome

    Ann Ophthalmol

    (1989)
  • O Chosidow et al.

    Hyperamylasemia in toxic epidermal necrolysis

    Arch Dermatol

    (1993)
  • BA Pruitt

    Burn treatment for the unburned

    JAMA

    (1987)
  • J Revuz et al.

    Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients

    Arch Dermatol

    (1987)
  • Cited by (0)

    Dr Foster is currently with The Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institute, Boston, MA. None of the authors have financial interests in any of the medications or products mentioned in this article.

    Yassine J. Daoud is the recipient of the Doris Duke Charitable Foundation and Harvard Medical School PASTEUR Clinical Research Fellowship.

    This feature is supported by an unrestricted educational grant from AstraZeneca LP

    View full text